Gastric Cancer Epidemiology

https://doi.org/10.1016/j.giec.2021.03.001Get rights and content

Section snippets

Key points

  • Globally, gastric cancer remains the fifth most common cancer and the third leading cause of cancer-related mortality.

  • In the United States, despite overall decreasing rates over the past five decades, incidence of noncardia gastric cancer is increasing among adults less than 50 years.

  • Helicobacter pylori is the main cause of gastric cancer, accounting for approximately 89% of distal gastric cancer cases worldwide.

  • Population-based programs of screening and surveillance and H pylori screening and

Worldwide Trends

According to GLOBOCAN estimates, there were 1,033,701 new cases of gastric cancer worldwide and 782,685 deaths related to gastric cancer in 2018.3 Gastric cancer was the fifth-most commonly diagnosed cancer type in 2018 (representing 5.7% of all cancer cases diagnosed) and was responsible for 8.2% of all deaths from cancer in 2018, making it the third-most common cause of cancer-related death after lung (18.4% of deaths) and colorectal (9.2% of deaths) cancers.3 In 2018, the global

Helicobacter pylori Infection

Chronic infection with H pylori is the main cause of gastric cancer, accounting for approximately 89% of distal gastric cancer cases worldwide.18 In 1994, the International Agency for Research on Cancer classified H pylori as a class I carcinogen for noncardia gastric cancer and reconfirmed this classification in 2009.19 Most H pylori infections are acquired during childhood and, once established, usually persist for life unless treated. There is substantial regional variation in prevalence,20

Prevention

Gastric cancer maintains a high case fatality rate of 75% throughout most of the world56 and is a main contributor to global disability-adjusted life-year burden.57 Mass screening for gastric cancer is generally not included in national strategies for cancer prevention because of high cost; decreasing incidence; and a lack of data on whom, when, and how to screen. To date, the clinical practice of gastric cancer prevention has focused on screening and surveillance and H pylori screening and

Future directions

Biomarkers for screening and risk triaging and clinical prediction rules that combine these biomarkers with established clinical and lifestyle factors for risk stratification need to be derived, optimized, and then validated in external populations. Future biomarker studies should aim to state the a priori plan for building statistical models; consider interactions, transformations, and splines; refrain from categorizing predictors; use and report model coefficients; aim for external

Summary

Further improvements in screening, treatment, and early diagnosis are needed for gastric cancer, which remains the third most common cause of cancer-related mortality worldwide. Although mass screening strategies could be beneficial, current modalities are not yet readily implementable in organized screening settings. Conversely, because the population risk (based on histology) can change rapidly, and H pylori eradication is effective, population-based programs of screening and treatment of H

Clinics care points

  • Although rates of noncardia gastric cancer in the United States continue to decrease among adults aged ≥50 years, the incidence of noncardia gastric cancer among persons aged less than 50 years is increasing, particularly among Hispanics, non-Hispanic Blacks, and Asian and Pacific Islanders.

  • Chronic infection with H pylori is the main cause of gastric cancer, accounting for approximately 89% of distal gastric cancer cases worldwide, and data demonstrate that eradicating H pylori reduces the

Disclosure

The authors have nothing to disclose.

First page preview

First page preview
Click to open first page preview

References (70)

  • L.G. Capelle et al.

    Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands

    Gastroenterology

    (2010)
  • I. Soerjomataram et al.

    Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions

    Lancet

    (2012)
  • A.P. Thrift et al.

    Prediction models for gastrointestinal and liver diseases: too many developed, too few validated

    Clin Gastroenterol Hepatol

    (2016)
  • M. Zeng et al.

    Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

    Lancet

    (2015)
  • J. Ferlay et al.
    (2018)
  • F. Bray et al.

    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

    CA Cancer J Clin

    (2018)
  • G. Luo et al.

    Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis

    Int J Cancer

    (2017)
  • M.M. Fidler et al.

    A global view on cancer incidence and national levels of the human development index

    Int J Cancer

    (2016)
  • Ferlay J, Colombet M, Bray F. Cancer incidence in five continents, CI5plus: International Agency for Research on Cancer...
  • W.F. Anderson et al.

    Age-specific trends in incidence of noncardia gastric cancer in US adults

    JAMA

    (2010)
  • U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool. U.S. Department of Health and...
  • Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence - SEER...
  • W.F. Anderson et al.

    The changing face of noncardia gastric cancer incidence among US non-Hispanic Whites

    J Natl Cancer Inst

    (2018)
  • Z. Wang et al.

    Increasing incidence of advanced non-cardia gastric cancers among younger Hispanics in the USA

    Dig Dis Sci

    (2020)
  • Z. Wang et al.

    Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis

    Int J Epidemiol

    (2018)
  • U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data...
  • Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence - SEER...
  • M. Plummer et al.

    Global burden of gastric cancer attributable to Helicobacter pylori

    Int J Cancer

    (2015)
  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of...
  • B. Peleteiro et al.

    Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage

    Dig Dis Sci

    (2014)
  • N.S. Akopyants et al.

    Analyses of the cag pathogenicity island of Helicobacter pylori

    Mol Microbiol

    (1998)
  • G. Suzuki et al.

    Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori

    Cancer Epidemiol Biomarkers Prev

    (2007)
  • H. Higashi et al.

    Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites

    Proc Natl Acad Sci U S A

    (2002)
  • M. Tatemichi et al.

    Ethnic difference in serology of Helicobacter pylori CagA between Japanese and non-Japanese Brazilians for non-cardia gastric cancer

    Cancer Sci

    (2003)
  • Tobacco smoke and involuntary smoking

    IARC Monogr Eval Carcinog Risks Hum

    (2004)
  • Cited by (52)

    • Analysis of phellinus igniarius effects on gastric cancer cells by atomic force microscopy

      2023, Micron
      Citation Excerpt :

      Gastric cancer is a major global health problem, and in its early stages, surgical resection may be curative, but many gastric cancer cases are found in their advanced stages with poor survival rates (Hsu and Raufi, 2021; Kim and Cho, 2021; Inoue, 2021; Cavatorta et al., 2018; Kong et al., 2022; Wang et al., 2021; He et al., 2021; Chen et al., 2021). Epidemiological studies have identified major contributors to gastric cancer, including the increasing of age, male sex, helicobacter pylori infection and smoking (Thrift and Nguyen, 2021; Koseki et al., 2021). Therefore, it is of great significance to find out specific drugs for the treatment of gastric cancer to replace chemotherapy, and to further evaluate the therapeutic effects and side effects of drugs on the human body.

    View all citing articles on Scopus
    View full text